glimepiride / Generic mfg. - LARVOL DELTA

A Comparative Evaluation of Dapagliflozin and Sulfonylureas in Patients With Type 2 Diabetes Mellitus. (PubMed, Cureus) - "Introduction Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone fails to achieve adequate glycemic control. Dapagliflozin was associated with greater HbA1c reduction, weight loss, lower blood pressure, and a lower risk of hypoglycemia, whereas glimepiride achieved greater fasting glucose reduction. Treatment selection should be individualized based on patient characteristics, comorbidities, and therapeutic goals."

Journal • Diabetes • Hypoglycemia • Hypotension • Infectious Disease • Metabolic Disorders • Movement Disorders • Type 2 Diabetes Mellitus

Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study. (PubMed, Biochem Biophys Rep) - "In this 48-week randomized, open-label, parallel-group trial, Japanese participants with type 2 diabetes and biopsy-confirmed MASLD received either tofogliflozin or glimepiride. The metabolic signature of SGLT2 inhibitors in the human liver is characterized by starvation-induced glucose production and hypovolemia-induced aestivation-like response. Serum succinate emerged as a potential biomarker associated with MASLD severity and treatment-related improvements under SGLT2 inhibition."

Journal • Diabetes • Hepatology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Drug-drug Interaction Between Alpinetin and Glimepiride and its Potential Mechanism in Rats. (PubMed, Int J Toxicol) - "The combination of glimepiride with alpinetin may increase the systemic exposure of glimepiride through inhibition of CYP2C9 activity. This likely contributes to the enhanced hypoglycemic effect observed, but also underscores the need for caution regarding the potential risk of hypoglycemia."

Journal • Preclinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus • CYP2C9

Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan. (PubMed, Diabetes Ther) - "Japan Registry of Clinical Trials (jRCT) (No. jRCTs041240011); registered 10 April 2024, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041240011 ."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypoglycemia • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Sarcopenia • Type 2 Diabetes Mellitus

Method Development for Simultaneous Quantification of Anti-diabetic Drugs in Combined Solid Dosage Form: A Focus on Sulfonylureas, Biguanides, and Thiazolidinediones. (PubMed, Curr Drug Res Rev) - "Sulfonylureas and Biguanides, particularly Gliclazide, Glimepiride, Glipizide, Glibenclamide, and Metformin, are commonly used in combination therapies for improved glycemic control. RP-HPLC and MS-based techniques can enhance data processing efficiency. These advancements will strengthen pharmaceutical quality control, ensure the safety and efficacy of anti-diabetic drug formulations, while optimizing therapeutic outcomes for diabetes management."

Journal • Review • Diabetes • Metabolic Disorders

Effects of luseogliflozin on arterial stiffness and body composition: A 48-week analysis using cardio-ankle vascular index and bioelectrical impedance analysis (EASD 2026) - "Therefore, we compared the effects of the SGLT2 inhibitor luseogliflozin versus glimepiride on arterial stiffness and body composition. In addition to its hypoglycemic effects and preventive effect on diabetic macular edema, luseogliflozin may improve arterial stiffness, promote weight loss, improve uric acid levels, and protect renal function."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Ophthalmic factors affecting SGLT2 inhibitor efficacy in diabetic macular oedema: post-hoc COMET trial analysis (EASD 2026) - "Materials and Sixty patients with DME requiring anti-VEGF therapy were randomized to receive either luseogliflozin (S) or glimepiride (G). This post-hoc analysis suggests that the therapeutic efficacy of SGLT2 inhibitors in DME varies depending on ophthalmic background, and that optimal patient selection is crucial. Combining SGLT2 inhibitors with anti-VEGF therapy in appropriately selected cases may enable more precise and effective treatment strategies."

Clinical • Retrospective data • Diabetes • Metabolic Disorders

Pharmaceutical polymer-based hydrogels for 3D bioprinted drug delivery and tissue engineering applications. (PubMed, J Biol Eng) - "Our research indicates that pharmaceutical-grade polymer-based hydrogels are promising candidates for skin tissue engineering and drug delivery through 3D bioprinting. The findings of this study underscore the potential of these formulations to advance bioprinting technologies and related applications."

Journal • Hematological Disorders

Albuminuria Not Attributable to Diabetic or Hypertensive Kidney Disease: Adult-Onset Minimal Change Disease Presenting With Nephrotic Syndrome in a Woman With Prediabetes and Hypertension. (PubMed, Cureus) - "The course was complicated by steroid-induced Cushingoid features and worsening glycemia, requiring temporary addition of glimepiride. By March 2026, the patient remained clinically well with excellent lipid and glycemic control. This case highlights the importance of early nephrology referral and kidney biopsy in adults with progressive albuminuria and edema, even when cardiometabolic comorbidities such as hypertension, prediabetes, and severe dyslipidemia coexist."

Journal • Cardiovascular • Diabetic Nephropathy • Dyslipidemia • Glomerulonephritis • Hepatitis C • Hypertension • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Mixed Hyperlipidemia • Nephrology • Renal Disease • Women's Health

A reproducible computational transcriptomic framework for cell-type-resolved fibroinflammatory-AKT remodeling in human heart failure. (PubMed, Comput Biol Chem) - "This study provides a computational transcriptomic framework linking reproducible human HF signatures, cell-type-resolved fibroinflammatory remodeling and perturbational genomic prioritization without claiming drug efficacy or AKT causality."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Molecular docking analysis of the interaction between metformin/glimepiride combination and organic cation transporter in diabetic patients. (PubMed, Wiad Lek) - " The results suggest that the glimepiride/metformin combination is a recommended treatment option for lowering blood glucose levels and treating type 2 diabetes."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • SLC22A1

Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD. (PubMed, J Gastroenterol) - P4 | "Gut microbial amino acid metabolism, particularly phenylalanine metabolism, is closely linked to liver fibrosis and molecular pathways in MASLD. Modulation of microbial metabolic functions may represent a promising therapeutic strategy beyond changes in microbial composition."

Journal • Diabetes • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Bisoprolol and Amlodipine Co-Administration with Glimepiride in a Diabetic Rat Model: A Statistical and Machine Learning Analysis. (PubMed, Pharmaceuticals (Basel)) - "Glimepiride+bisoprolol emerged as the most effective regimen, supporting cardioselective β-blockade as a metabolically favorable antihypertensive partner for sulfonylurea therapy and warranting clinical confirmation. More broadly, these results provide a preclinical, evidence-based rationale for selecting metabolically favorable antihypertensives in patients with coexisting T2DM and hypertension, with the potential to improve glycemic outcomes and reduce the risk of adverse drug-disease interactions during combination therapy."

Journal • Preclinical • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Sulfonylureas beyond diabetes: A comprehensive review on anticancer and off-target effects (1956-2025). (PubMed, Eur J Med Chem) - "Glibenclamide emerges primarily as a chemosensitizing and transporter-modulating compound, gliclazide as a drug with antioxidant, anti-inflammatory, and DNA-protective properties, glimepiride as a promising synergistic agent with additional AKR1C3-inhibitory activity, tolbutamide as a modulator of gap-junction signaling and mitochondrial stability, and chlorpropamide derivatives as ALDH-targeting chemosensitizers. At the same time, the review highlights major translational constraints, including weak baseline cytotoxicity for most SUs, frequent exposure mismatches between experimental and clinical settings, heterogeneous safety profiles, photoreactivity, and limited commercial incentives for development, while also outlining practical strategies to address these limitations. Overall, SUs should not be viewed as a single repurposing candidate, but as a chemically related set of drugs that require indication-specific and compound-specific selection for future oncology..."

Journal • Review • Diabetes • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus

Octreotide Treatment for Persistent Sulfonylurea-Induced Hypoglycemia in Acute Renal Insufficiency (ENDO 2026) - "He had type 2 diabetes, managed with glimepiride 1mg twice daily via feeding tube... This case demonstrates how impaired renal clearance can prolong sulfonylurea effects, resulting in persistent hypoglycemia days after the last dose. Octreotide acts by inhibiting insulin secretion at the pancreatic beta cell level, rapidly stabilizing blood glucose and significantly reducing the risk of recurrent hypoglycemic episodes compared to dextrose alone. Octreotide is safe and effective in both adult and pediatric populations, including in those with comorbidities such as congestive heart failure or renal failure, where prolonged IV dextrose infusion may pose additional risks such as fluid overload."

Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Endocrine Disorders • Heart Failure • Hypoglycemia • Metabolic Disorders • Nephrology • Renal Disease • Squamous Cell Carcinoma • Type 2 Diabetes Mellitus

The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides. (PubMed, Drug Des Devel Ther) - "Studies consistently show that ASD formulations of antidiabetic drugs such as glimepiride, repaglinide, gliclazide, gliquidone, and glyburide enhance insulin secretion and contribute to more effective glycemic control, showing the potential of ASD in improving the therapeutic performance of poorly soluble antidiabetic agents. By enhancing solubility, stability, and bioavailability, ASD technology holds significant promise for developing more potent and effective antidiabetic therapies, ultimately supporting better patient care and addressing the global burden of diabetes mellitus."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Time-to-Event Nonadditive Analysis Identifies Novel Genetic Variants Associated with Treatment Response and Weight Loss in the GRADE Clinical Trial (ADA 2026) - "We hypothesized that an alternative whole-genome regression including dominant (full effect by one allele copy) and recessive (only homozygous have an effect) models would increase statistical power. The GRADE Genetics Study examined 4,538 participants on metformin and randomized to glargine, glimepiride, liraglutide, or sitagliptin. To sum up, we identified novel loci associated with treatment response, which may support T2D personalized treatment."

Clinical • Metabolic Disorders

Characterization of Metabolites in Plant-Based Milk Yogurt Enriched with Wolffia globosa to Improve Bionutritional and Functional Properties. (PubMed, Int J Mol Sci) - "Molecular docking analysis revealed that key metabolites, including vignatic acid B, glimepiride, and indoramin, exhibited strong binding affinities with the active sites of α-amylase (PDB: 2GVY, Aspergillus niger) and α-glucosidase (PDB: 3A4A, Saccharomyces cerevisiae). These findings indicate that phytonutrient compounds, particularly indoramin, play a significant role in enhancing the nutritional composition and functional properties of RBRM-WGP yogurt for potential applications in food processing."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. (PubMed, BMJ Open Diabetes Res Care) - P | "Glyburide was associated with a modestly lower risk of kidney complications, despite a higher risk of hypoglycemia, while glipizide was associated with a higher risk of kidney complications. These hypothesis-generating findings suggest important within-class differences that warrant consideration in clinical decision-making and future research. Despite rigorous prespecified causal inference analytic methods, the risk of unmeasured confounding and bias by indication with the use of observational data remains."

Clinical • HEOR • Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Three Decades of Glimepiride Analysis: A Review of Analytical and Bioanalytical Methods. (PubMed, Biomed Chromatogr) - "In addition, bioanalytical applications related to pharmacokinetic, pharmacodynamic and bioequivalence studies are discussed. This review provides an organized summary of analytical developments for glimepiride fills notable gap and serves as a valuable reference for pharmaceutical analysts in method selection, method development and quality control studies involving this drug."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Activated charcoal in the stomach: Clinical familiarity and limited gross recognition. (PubMed, Forensic Sci Med Pathol) - "Open bottles of amlodipine and glimepiride were found on his person...This case illustrates the characteristic gross appearance of activated charcoal in the stomach and discusses its potential to mimic other causes of black gastric contents, including gastrointestinal hemorrhage, caustic ingestion, Wischnewsky spots, hydrocarbons, black esophagus, and iron deposition. Awareness of this finding and careful correlation of gross autopsy findings with medical history and toxicologic results are essential to avoid misinterpretation and diagnostic error in forensic practice."

Journal • Cardiovascular • Critical care • Diabetes • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Disorders • Metabolic Disorders • Oncology • Prostate Cancer • Solid Tumor

Glycemic Control and Utilization Risk With the Conversion of Glimepiride to Glipizide in Adults 64 Years and Older at an Integrated Health Care System. (PubMed, J Am Geriatr Soc) - "Patients 64 years and older converted from long-acting to short-acting sulfonylureas had no change in glycemic control, and lower rates of ED or hospital utilization at 4-months were observed. This paper reaffirms the Beers Criteria statement that shorter-acting sulfonylureas are preferred over longer-acting sulfonylureas."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders

Sodium-glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial. (PubMed, J Diabetes Investig) - "In this exploratory analysis, SGLT2 inhibition was associated with fewer intravitreal injections in patients meeting the CRT-based mild criteria. These findings are hypothesis-generating and warrant confirmation in future prospective studies."

Journal • Retrospective data • Diabetic Macular Edema • Ophthalmology

Glimepiride alleviates blood-brain barrier disruption and neuroinflammation in mice with intracerebral haemorrhage. (PubMed, Ann Med) - "GPD also decreased neuronal apoptosis, as evidenced by the upregulation of BCL-2, downregulation of BAX, and decreased number of TUNEL-positive cells. In ICH injury, GPD protects the integrity of the blood-brain barrier, alleviates neuroinflammation, improves neurological functions, mitigates brain oedema, lessens haematoma volume, and inhibits the apoptosis of neural cells."

IO biomarker • Journal • Preclinical • Cardiovascular • CNS Disorders • Inflammation • Ischemic stroke • Movement Disorders • Parkinson's Disease • Vascular Neurology • BAX • BCL2 • MMP9 • MPO • OCLN • TJP1

CT-L03-301: Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy (clinicaltrialsregister.eu) - P2/3 | N=224 | Completed | Sponsor: Celltrion Inc. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus